Focused On-demand Library for DNA-binding protein SATB1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q01826

UPID:

SATB1_HUMAN

Alternative names:

Special AT-rich sequence-binding protein 1

Alternative UPACC:

Q01826; B3KXF1; C9JTR6; Q59EQ0

Background:

DNA-binding protein SATB1, also known as Special AT-rich sequence-binding protein 1, plays a pivotal role in chromatin organization and nuclear architecture. It acts as a transcriptional repressor and is involved in the maturation of immune T-cells, erythroid differentiation, and apoptosis. SATB1's interaction with DNA at special AT-rich sequences and its ability to recruit chromatin remodeling enzymes highlight its significance in gene expression regulation.

Therapeutic significance:

SATB1 is linked to Kohlschutter-Tonz syndrome-like and Developmental delay with dysmorphic facies and dental anomalies, diseases characterized by developmental delays, dysmorphic facial features, and dental anomalies. Understanding the role of SATB1 could open doors to potential therapeutic strategies for these conditions.